Report Overview

The South Korea atopic dermatitis treatment market size stood at around USD 39.60 million in 2020 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.

Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease that causes severe pruritus and sleep disturbance.Most cases of AD occur in infants and children younger than five years of age.AD is caused by the interplay between various genetic and environmental factors. The gene encoding filaggrin (FLG) has been most consistently reported as being responsible for AD.Environmental factors such as physical trauma, allergens, and environmental tobacco smoke are also known to contribute to the development of AD. However, the exact pathogenesis is still under investigation. Because of its high prevalence, low quality of life, and possible progression to asthma, AD is regarded as one of the major health problems in children. Some common symptoms of atopic dermatitis are scaly, dry skin, rash, cracked skin that hurts and sometimes bleeds, skin creasing on the palms of the hand or under the eye, darkening of skin around the eyes.



Market Drivers

Increase in incidence of atopic dermatitis in children year on year is predicted to enhance the market growth. Efforts made by the domestic companies for the development of novel drugs, growing healthcare expenditure, climate change, escalating pollution levels and rise in R&D by pharmaceuticals companies are all factors driving the market. Advent of biologics will also impact the market positively. Lack of awareness in people acts as a market restraint.